Exportar registro bibliográfico


Metrics:

Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation (2017)

  • Authors:
  • USP affiliated authors: SIMOES, BELINDA PINTO - FMRP ; COVAS, DIMAS TADEU - FMRP
  • Unidade: FMRP
  • DOI: 10.1038/bmt.2017.35
  • Subjects: LEUCEMIA; DOENÇA ENXERTO-HOSPEDEIRO; CÉLULAS-TRONCO; SOBREVIVÊNCIA LIVRE DE DOENÇA
  • Agências de fomento:
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso à fonteDOI
    Informações sobre o DOI: 10.1038/bmt.2017.35 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed

    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      DOTOLI, G. M.; SANTIS, G. C. de; ORELLANA, M. D.; et al. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transplantation, London, v. 52, n. 6, p. 859-862, 2017. Disponível em: < http://dx.doi.org/10.1038/bmt.2017.35 > DOI: 10.1038/bmt.2017.35.
    • APA

      Dotoli, G. M., Santis, G. C. de, Orellana, M. D., Prata, K. de L., Caruso, S. R., Fernandes, T. R., et al. (2017). Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 52( 6), 859-862. doi:10.1038/bmt.2017.35
    • NLM

      Dotoli GM, Santis GC de, Orellana MD, Prata K de L, Caruso SR, Fernandes TR, Colturato VAR, Kondo AT, Hamerschlak N, Simões BP, Covas DT. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation [Internet]. Bone Marrow Transplantation. 2017 ; 52( 6): 859-862.Available from: http://dx.doi.org/10.1038/bmt.2017.35
    • Vancouver

      Dotoli GM, Santis GC de, Orellana MD, Prata K de L, Caruso SR, Fernandes TR, Colturato VAR, Kondo AT, Hamerschlak N, Simões BP, Covas DT. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation [Internet]. Bone Marrow Transplantation. 2017 ; 52( 6): 859-862.Available from: http://dx.doi.org/10.1038/bmt.2017.35

    Referências citadas na obra
    Jagasia M, Arora M, Flowers MED, Chao NJ, McCarthy PL, Cutler CS et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012; 119: 296–307.
    Ferrara JL, Levine JE, Reddy P, Holler E . Graft-versus-host disease. Lancet 2009; 373: 1550–1561.
    Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012; 158: 30–45.
    Koreth J, Antin JH . Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol 2008; 1: 111.
    Alousi AM, Weisdorf DJ, Logan BR, Bolaños-Meade J, Carter S, Difronzo N et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 2009; 114: 511–517.
    Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579–1586.
    Xhaard A, Rocha V, Bueno B, de Latour RP, Lenglet J, Petropoulou A et al. Steroid-refractory acute GVHD: lack of long-term improved survival using new generation anticytokine treatment. Biol Blood Marrow Transplant 2012; 18: 406–413.
    Deeg HJ . How I treat how I treat refractory acute GVHD. Blood 2007; 109: 4119–4126.
    Ho VT, Cutler C . Current prevention and therapies in acute GVHD. Best Pract Res Clin Haematol 2008; 21: 223–237.
    Garnett C, Apperley JF, Pavlů J . Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol 2013; 4: 366–378.
    Najar M, Raicevic G, Fayyad-Kazan H, Bron D, Toungouz M, Lagneaux L . Mesenchymal stromal cells and immunomodulation: a gathering of regulatory immune cells. Cytotherapy 2016; 18: 160–171.
    Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M et al. Treatment of severe acute graft-versus-host disease with third party haplindentical mesenchymal stem cells. Lancet 2004; 363: 1439–1441.
    Kebriaei P, Robinson S . Treatment of graft-versus-host-disease with mesenchymal stromal cells. Cytotherapy 2011; 13: 262–268.
    von Bahr L, Sundberg B, Lönnies L, Sander B, Karbach H, Hägglund H et al. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant 2012; 18: 557–564.
    Ball LM, Bernardo ME, Roelofs H, van Tol MJD, Contoli B, Zwaginga JJ et al. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III–IV acute graft-versus-host disease. Br J Haematol 2013; 163: 501–509.
    Resnick IB, Barkats C, Shapira MY, Stepensky P, Bloom AI, Shimoni A et al. Treatment of severe steroid resistant acute GVHD with mesenchymal stromal cells (MSC). Am J Blood Res 2013; 3: 225–238.
    Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW et al. Allogeneic human mesenchymal stem cell therapy (Remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. Biol Blood Marrow Transplant 2014; 20: 229–235.
    Herrmann RP, Sturm MJ . Adult human mesenchymal stromal cells and the treatment of graft versus host disease. Stem Cells Cloning 2014; 7: 45–52.
    Introna M, Lucchini G, Dander E, Galimberti S, Rovelli A, Balduzzi A et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients. Biol Blood Marrow Transplant 2014; 20: 375–381.
    Sánchez-Guijo F, Caballero-Velázquez T, López-Villar O, Redondo A, Parody R, Martínez C et al. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 2014; 20: 1580–1585.
    Muroi K, Miyamura K, Okada M, Yamashita T, Murata M, Ishikawa T et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study. Int J Hematol 2016; 103: 243–250.
    von Dalowski F, Kramer M, Wermke M, Wehner R, Rollig C, Alakel N et al. Mesenchymal stromal cells for treatment of acute steroid-refractory graft versus host disease: clinical responses and long-term outcome. Stem Cells 2016; 34: 357–366.
    Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8: 315–317.
    Caruso SR, Orellana MD, Mizukami A, Fernandes TR, Fontes AM, Suazo CAT et al. Growth and functional harvesting of human mesenchymal stromal cells cultured on a microcarrier-based system. Biotechnol Prog 2014; 30: 889–895.
    Kaipe H, Erkers T, Sadeghi B, Ringdén O . Stromal cells–are they really useful for GVHD? Bone Marrow Transplant 2014; 49: 737–743.
    Hashmi S, Ahmed M, Murad MH, Litzow MR, Adams RH, Ball LM et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol 2016; 3: e45–e52.

Digital Library of Intellectual Production of Universidade de São Paulo     2012 - 2020